Sponsors (16)
The bill prolongs and strengthens oversight, transparency, and research-informed access for ALS and related conditions—potentially improving patient access and program effectiveness—at the cost of more reporting, administrative burden, legal ambiguity in one statutory change, and higher taxpayer-funded program costs.
Patients with ALS and hospitals/health-systems keep access to the Act's programs and federal coordination for an additional five years (2027–2031), preserving ongoing supports and expedited pathways the law provides.
People with ALS may get broader, research-informed access to investigational drugs because applicants must describe how expanded-access data will support ALS research, potentially increasing evidence generation and patient access.
Clarifying eligible trial definitions and requiring clearer renewal/enrollment and safety data gives grant reviewers, HHS, and applicants better information, reducing ambiguity for applicants and smoothing grant administration and oversight.
Taxpayers face increased federal spending and potential new funding requests over the extended authorization period to support the programs, FDA analyses, and any recommended implementation actions.
Expanded reporting and assessment requirements create significant additional administrative burden for HHS and FDA that could require more staff or funding and temporarily divert agency resources from on-the-ground program delivery.
Grantees, drug sponsors, and research institutions must share more trial and safety data promptly, increasing compliance costs and administrative workload for hospitals and researchers.
Based on analysis of 6 sections of legislative text.
Reauthorizes the ALS therapies program through 2031 and tightens grant, FDA action-plan, and reporting rules for ALS and rare neurodegenerative disease activities.
Official title: Amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.
Introduced April 30, 2026 by Lisa Murkowski · Last progress August 10, 2026
Extends and updates the federal program that supports development and patient access to therapies for amyotrophic lateral sclerosis (ALS) by reauthorizing the statute for another five-year window and revising FDA grant, reporting, and action-plan requirements. It clarifies grant application and review rules for ALS expanded-access grants, expands FDA action-plan content to include rare neurodegenerative diseases, requires a new HHS report timeline, and makes minor technical corrections. The bill does not create new funding levels; it shifts the authorized five‑year period forward (2027–2031), tightens grant application assurances and reviewer duties, adds reporting and renewal-assessment obligations, and requires future FDA action plans to describe prior implementation, planned actions, and barriers with optional resource estimates.